Elacestrant in combination with ribociclib or everolimus demonstrates promising efficacy and manageable safety in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who experienced disease progression after endocrine therapy plus CDK4/6 inhibitors, Watch Video ›

The SERENA-6 trial reveals camizestrant's potential to improve outcomes in hormone receptor (HR)-positive, HER2-negative breast cancer by utilizing circulating tumor DNA (ctDNA)-guided therapy towards ESR1 mutations before disease progression. Watch Video ›

Patient-reported outcomes from EMBER-3 demonstrate that imlunestrant improves global health status/quality of life and physical function in patients with ESR1 mutations in estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Watch Video ›

In this fourth installment, Paula reviews relevant data for immunotherapies currently FDA approved for patients with advanced endometrial cancer. Watch Video ›

In this third installment, Paula will discuss the importance and relevance of data science in advancing the field of nursing. Watch Video ›

In this first installment, Paula will discuss recent data of immunotherapy in patients with advanced endometrial cancer and highlight nursing considerations to help manage side effects. Watch Video ›

In this second installment, Paula will discuss a health equity study investigating the association of neighborhood socioeconomic deprivation in patients with gynecologic cancers. Watch Video ›

Dr Erica Mayer explains the results of a study utilizing the novel SERD SIM0270, as monotherapy and in combination, in the treatment of patients with estrogen receptor–positive, HER2-negative advanced breast cancer. Watch Video ›

Dr Erica Mayer discusses an analysis of the EMERALD study, which explores the effects of variant allele frequencies on outcomes for patients with advanced breast cancer being treated with elacestrant. Watch Video ›

Dr Erica Mayer comments on real-world outcomes for elacestrant derived from the GuardantINFORM database, and describes which patients elacestrant therapy may be best for. Watch Video ›